Suspension of trading
Acorda Therapeutics Stock OTC Markets
Stocks
ACOR
US00484M7002
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-10.00% | -99.91% |
| 13/08/24 | First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc. | CI |
| 07/08/24 | Modified First Amended Joint Liquidation Plan Approved for Acorda Therapeutics, Inc. | CI |
| 1 week | -10.00% | ||
| 1 month | -87.85% | ||
| 3 months | -98.41% | ||
| 6 months | -99.90% | ||
| Current year | -99.91% |
| 1 week | 0 |  | 0.02 |
| 1 month | 0 | | 0.15 |
| 3 years | 0 | | 99.8 |
| 5 years | 0 | | 535.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sofia Ali
COO | Chief Operating Officer | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -10.00% | -99.92% | -99.98% | 16.77K | |
| +1.03% | +7.52% | +54.74% | +114.98% | 55.58B | |
| +2.72% | +3.06% | +53.28% | +47.85% | 43.47B | |
| +1.12% | +1.06% | -14.15% | -17.13% | 22.64B | |
| +1.17% | -6.74% | -0.13% | +394.19% | 20.96B | |
| +3.81% | -4.13% | +16.62% | -30.70% | 15.79B | |
| +0.15% | +2.24% | +9.06% | -39.50% | 15.3B | |
| -0.69% | +1.22% | +28.24% | +176.72% | 13.45B | |
| +5.27% | +6.41% | +21.05% | - | 11.74B | |
| +1.61% | +1.17% | +90.79% | +212.97% | 10.96B | |
| Average | +1.67% | +0.26% | +15.96% | +84.38% | 23.32B | |
| Weighted average by Cap. | +1.58% | +1.60% | +33.63% | +100.77% |
Employees
-
- Stock Market
- Stocks
- ACOR.Q Stock
- ACOR Stock
Select your edition
All financial news and data tailored to specific country editions
